GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Maxigen Biotech Inc (TPE:1783) » Definitions » Cash Ratio

Maxigen Biotech (TPE:1783) Cash Ratio : 2.22 (As of Jun. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Maxigen Biotech Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Maxigen Biotech's Cash Ratio for the quarter that ended in Jun. 2024 was 2.22.

Maxigen Biotech has a Cash Ratio of 2.22. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Maxigen Biotech's Cash Ratio or its related term are showing as below:

TPE:1783' s Cash Ratio Range Over the Past 10 Years
Min: 1.15   Med: 4.37   Max: 8.66
Current: 2.22

During the past 13 years, Maxigen Biotech's highest Cash Ratio was 8.66. The lowest was 1.15. And the median was 4.37.

TPE:1783's Cash Ratio is ranked better than
67.95% of 858 companies
in the Medical Devices & Instruments industry
Industry Median: 1.11 vs TPE:1783: 2.22

Maxigen Biotech Cash Ratio Historical Data

The historical data trend for Maxigen Biotech's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maxigen Biotech Cash Ratio Chart

Maxigen Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.34 2.57 4.65 5.29 3.29

Maxigen Biotech Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.12 2.43 3.29 3.56 2.22

Competitive Comparison of Maxigen Biotech's Cash Ratio

For the Medical Instruments & Supplies subindustry, Maxigen Biotech's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maxigen Biotech's Cash Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Maxigen Biotech's Cash Ratio falls into.



Maxigen Biotech Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Maxigen Biotech's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=432.582/131.373
=3.29

Maxigen Biotech's Cash Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash Ratio (Q: Jun. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=522.288/235.598
=2.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Maxigen Biotech  (TPE:1783) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Maxigen Biotech Cash Ratio Related Terms

Thank you for viewing the detailed overview of Maxigen Biotech's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Maxigen Biotech Business Description

Traded in Other Exchanges
N/A
Address
No. 88, Keji 1st Rd, Guishan District, Taoyuan City, TWN, 333
Maxigen Biotech Inc specializes in the developing, manufacturing, and marketing of biomedical and cosmeceutical skincare products. It provides medical devices for orthopedic, ophthalmic, dental, and surgical applications. Skincare product categories include mask series, facial cleansing series, and body care series. The biomedical products segment is primarily engaged in the manufacturing and sales of collagen and bone materials, which forms the majority chunk of the revenue of the group. The consumer products segment is engaged in the manufacturing and sales of beauty care products.

Maxigen Biotech Headlines

No Headlines